{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/china-world-advancing-biotechs-oncology-therapy-achieve-fda-accelerated-approval#webpage",
"url": "https://www.fortrea.com/insights/china-world-advancing-biotechs-oncology-therapy-achieve-fda-accelerated-approval",
"name": "From China to the world: Advancing a biotech’s oncology therapy to achieve FDA accelerated approval",
"description": "Explore this Fortrea Case Study highlighting the successful clinical development and regulatory advancement of an oncology therapy originating in China and progressing toward FDA approval. As Chinese biopharmaceutical companies increasingly expand into global markets, sponsors face complex challenges associated with aligning regional clinical development programs with international regulatory expectations, generating globally relevant clinical evidence, and navigating cross-regional development pathways. This case study demonstrates how Fortrea partnered with the sponsor to support oncology clinical development, regulatory planning, operational execution, and global development strategies designed to facilitate regulatory acceptance beyond China. The resource highlights the importance of integrating global clinical trial expertise, regulatory insights, patient enrollment planning, study execution capabilities, and oncology therapeutic knowledge to support development programs intended for international submissions. It also illustrates how collaboration across regions, strategic trial planning, and regulatory alignment can help sponsors address the requirements of global health authorities while advancing innovative oncology therapies toward broader patient access. Through its experience in oncology drug development, global clinical operations, and regulatory strategy, Fortrea helped support a development pathway that contributed to achieving FDA approval objectives and expanding opportunities for a China-developed oncology treatment within global healthcare markets."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "From China to the world: Advancing a biotech’s oncology therapy to achieve FDA accelerated approval",
"item": "https://www.fortrea.com/insights/china-world-advancing-biotechs-oncology-therapy-achieve-fda-accelerated-approval"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/china-world-advancing-biotechs-oncology-therapy-achieve-fda-accelerated-approval#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/china-world-advancing-biotechs-oncology-therapy-achieve-fda-accelerated-approval#webpage"
},
"headline": "Accelerating FDA Approval Through Strategic Oncology Development in China | Fortrea Case Study",
"description": "Explore this Fortrea Case Study highlighting the successful clinical development and regulatory advancement of an oncology therapy originating in China and progressing toward FDA approval. As Chinese biopharmaceutical companies increasingly expand into global markets, sponsors face complex challenges associated with aligning regional clinical development programs with international regulatory expectations, generating globally relevant clinical evidence, and navigating cross-regional development pathways. This case study demonstrates how Fortrea partnered with the sponsor to support oncology clinical development, regulatory planning, operational execution, and global development strategies designed to facilitate regulatory acceptance beyond China. The resource highlights the importance of integrating global clinical trial expertise, regulatory insights, patient enrollment planning, study execution capabilities, and oncology therapeutic knowledge to support development programs intended for international submissions. It also illustrates how collaboration across regions, strategic trial planning, and regulatory alignment can help sponsors address the requirements of global health authorities while advancing innovative oncology therapies toward broader patient access. Through its experience in oncology drug development, global clinical operations, and regulatory strategy, Fortrea helped support a development pathway that contributed to achieving FDA approval objectives and expanding opportunities for a China-developed oncology treatment within global healthcare markets.",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-03-18",
"dateModified": "2026-03-18",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-03/china-oncology-fda-approval.pdf",
"encodingFormat": "application/pdf"
}
}
]
}